Mindset

Mindset Pharma to Participate in Upcoming Conferences in December 2022

Retrieved on: 
Tuesday, December 6, 2022
Conference, Mental health, Mental, Drug discovery, MSET, FSE, Otsuka Pharmaceutical, CSE, Future, CSO, Development, Pharmaceutical industry, Mindset

Mr. Lanthier and Mr. Araujo will participate in a fireside chat with Andrew Partheniou, Stifel Research Analyst, at 3:30 p.m.

Key Points: 
  • Mr. Lanthier and Mr. Araujo will participate in a fireside chat with Andrew Partheniou, Stifel Research Analyst, at 3:30 p.m.
  • Canaccord Genuity Symposium on New Paradigms and Treatment Approaches in Mental Health to be held virtually on Tuesday, December 13, 2022.
  • Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

Mindset Pharma CEO, James Lanthier Issues Letter to Shareholders

Retrieved on: 
Wednesday, November 30, 2022
Well, Psilocybin, Scientific Advice Mechanism, Science, MDMA, Organization, Pharmacology, Otsuka Pharmaceutical, Health care, IND, Partnership, Patient, FSE, Major depressive disorder, Tryptamine, CGMP, Family 1, Thermoregulation, Half-life, CNS, Patent, Depression, Agreement, CSO, Research, Development, CSE, Clinical trial, MSET, DMT, CDMO, Drug discovery, Contract research organization, Safety, MDD, Management, Pharmaceutical industry, MDXX, Family, Mindset

TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (Mindset or the Company) today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset.

Key Points: 
  • TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (Mindset or the Company) today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset.
  • Mindset is focused on a singular goal to bring best-in-class optimized psychedelic medications to patients in need.
  • Mindset has an unmatched track record of strategically partnering with organizations that can help us advance and commercialize our innovations.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

Mindset Pharma and PharmAla Enter into Exclusive Sales Agreement for the Sale and Distribution of Pharmaceutical Grade Psilocybin

Retrieved on: 
Wednesday, November 16, 2022
Otsuka Pharmaceutical, Partnership, FSE, CGMP, Research, Therapy, Psilocybin, Development, CSE, MSET, DEA, Drug discovery, MDMA, Pharmaceutical industry, Fine chemical, MDXX, Psychedelic drug, Mindset

Under the sales agreement, PharmAla will be the exclusive global reseller of Mindsets cGMP (i.e.

Key Points: 
  • Under the sales agreement, PharmAla will be the exclusive global reseller of Mindsets cGMP (i.e.
  • In addition to forging new ground in next generation psychedelic drug discovery, Mindset has also developed a patent-pending, highly scalable psilocybin synthesis technology.
  • We have chosen PharmAla as a partner because of their track record in working with clinical researchers, and existing sales infrastructure to sell pharmaceutical grade psychedelic compounds.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement

Retrieved on: 
Wednesday, November 16, 2022
Otsuka Pharmaceutical, Partnership, FSE, CGMP, GMP, Research, Therapy, Psilocybin, Development, CSE, MSET, DEA, Drug discovery, MDMA, Pharmaceutical industry, Fine chemical, Online shopping, MDXX, Psychedelic drug, Mindset

Under the sales agreement, PharmAla will be the exclusive global reseller of Mindsets cGMP (i.e.

Key Points: 
  • Under the sales agreement, PharmAla will be the exclusive global reseller of Mindsets cGMP (i.e.
  • In addition to forging new ground in next generation psychedelic drug discovery, Mindset has also developed a patent-pending, highly scalable psilocybin synthesis technology.
  • We have chosen PharmAla as a partner because of their track record in working with clinical researchers, and existing sales infrastructure to sell pharmaceutical grade psychedelic compounds.
  • PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA.

Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug Candidate

Retrieved on: 
Monday, November 14, 2022
Psilocybin, Psilocin, MSET, CSE, Mouse, EC50, BT, Pathology, Society for Neuroscience, FSE, Pharmacokinetics, ED50, Otsuka Pharmaceutical, LMA, Prodrug, Safety, Society, RATS, Depression, CSO, Development, Drug discovery, Behavior, SC, SFN, Patient, Pharmaceutical industry, Emax, Mindset, Neuroscience

Joseph Araujo, Chief Scientific Officer, Director of Mindset Pharma, presented the findings at Neuroscience 2022 hosted by the Society of Neuroscience (SfN) in a poster titled The Preclinical Safety, Behavioural and Pharmacokinetics Properties of MSP-1014, a Novel Prodrug of Psilocin .

Key Points: 
  • Joseph Araujo, Chief Scientific Officer, Director of Mindset Pharma, presented the findings at Neuroscience 2022 hosted by the Society of Neuroscience (SfN) in a poster titled The Preclinical Safety, Behavioural and Pharmacokinetics Properties of MSP-1014, a Novel Prodrug of Psilocin .
  • Psilocybin is a dihydrogen phosphonate prodrug of psilocin, which is thought to mediate antidepressant effects primarily by activation of 5-HT2A receptor subtype.
  • MSP-1014 was also evaluated in a drug discrimination assay in which rats were trained to discriminate a psilocybin cue from saline.
  • Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.

GumGum Integrates Attention Measurement Into All Contextual Campaigns

Retrieved on: 
Tuesday, November 8, 2022
Ecosystem, GLOBE, Advertising, North, Technology, Behavior, Face, ROI, United Kingdom, AIP, Attention, Science, Playground, Growth, Time, CEO, Mindset, Industry, Creative industries

LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The leader in contextual intelligence, GumGum , announced today that advanced attention measurement and optimization will be incorporated into all display creative campaigns running on the GumGum platform in 2023.

Key Points: 
  • LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The leader in contextual intelligence, GumGum , announced today that advanced attention measurement and optimization will be incorporated into all display creative campaigns running on the GumGum platform in 2023.
  • Over our four years of studying attention weve proven that when brands focus on boosting attention many other key performance indicators follow, says Rob Hall, CEO, Playground xyz.
  • Both GumGum and Playground xyz have experienced accelerated growth as the industry shifts to a cookie-free world and grapples with the burgeoning attention economy, in which Playground xyz has been the trusted source of attention measurement since 2016.
  • The company has built the worlds first technology stack that integrates visual attention measurement, analytics and media optimization called the Attention Intelligence Platform.

Mindset Pharma Announces Poster Presentations at Two Upcoming Scientific Conferences

Retrieved on: 
Thursday, October 27, 2022
MSET, Drug discovery, Behavior, PD, Development, Safety, Psychedelic drug, Prodrug, Otsuka Pharmaceutical, CSE, Society, CA, GLOBE, Drug development, Benchmarking, FSE, Society for Neuroscience, Pharmaceutical industry, Generic drug, Pharmacokinetics, Neuroscience, Mindset, Psilocybin

TORONTO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced upcoming poster presentations related to its second-generation psilocybin-like lead drug candidate, MSP-1014 at two upcoming scientific conferences.

Key Points: 
  • The poster presentations compare a novel prodrug of psilocin, MSP-1014, to psilocybin in preclinical studies evaluating safety, behavioral and pharmacokinetics properties of both psilocin prodrugs.
  • In addition, collaborative work will be presented on benchmarking psilocybin in various animal models.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.
  • Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds.

T.J.Maxx and "Find Your Maxx" Partner and Mentor Yvonne Orji Launch Interactive Workshop Series for Women Everywhere

Retrieved on: 
Thursday, October 13, 2022
Movement, Assistant, Woman, Mentorship, Find, TJ Maxx, Instagram, Mindset, Maxx, Success, Failure, Tourism, Management, Marketing

FRAMINGHAM, Mass., Oct. 13, 2022 /PRNewswire/ -- As part of its mission to provide women with essential tools that empower them to ditch the fear of failure and put themselves first, T.J.Maxx is launching its Find Your Maxx workshop series this weekend. Find Your Maxx is part of The Maxx You Project, T.J.Maxx's ongoing initiative to support women with tools and resources as they navigate the process of becoming their most authentic, unapologetic selves.

Key Points: 
  • Now, Yvonne will kick off an interactive virtual workshop series with the 'Maxx Your Mindset' session, co-hosted by seasoned life coach Sophia Casey.
  • The workshop will take place on Instagram Live via @tjmaxx on October 15th at 4:00pm ET.
  • The workshop series is designed to provide women with actionable tools to become their most authentic self and includes themes like 'Maxx Your Mentors' and 'Maxx Your Confidence.'
  • "We look forward to kicking off the Find Your Maxx workshop series and continuing this impactful movement we've started."

GumGum Breaks the Billion Dollar Mark as Marketers Double Down on Privacy-First, Contextual Approaches

Retrieved on: 
Thursday, October 6, 2022
Jeep, Meredith, Advertising, Growth, Media, Attention, CAGR, Privacy, Technology, SAP, Ecosystem, MRC, CTV, GLOBE, Mindset, Internet, Contextual, Renewable energy, Video game console, Vodafone, Canon

SANTA MONICA, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- GumGum, a contextual-first, global digital advertising platform, today announces that it has broken the $1 billion dollar ad spend milestone.

Key Points: 
  • SANTA MONICA, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- GumGum, a contextual-first, global digital advertising platform, today announces that it has broken the $1 billion dollar ad spend milestone.
  • Were thrilled to mark this milestone, which we see as a significant moment in our ongoing journey and growth here at GumGum, after championing contextual technology for over a decade, said GumGum CEO Phil Schraeder.
  • Bolstered by recent partnerships, GumGum is moving aggressively into the gaming and connected TV (CTV) environments in 2023.
  • GumGum is a contextual-first, global digital advertising platform that captures peoples attention, without the use of personal data.

Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio

Retrieved on: 
Wednesday, October 5, 2022
FSE, CSO, Development, IND, Family II, Otsuka Pharmaceutical, LLC, Patient, Mental health, Treatment, Drug discovery, CSE, CEO, CNS, Patent, Psilocybin, GLOBE, USPTO, Half-life, MSET, CRO, Pharmaceutical industry, Mindset

Through a world class scientific collaboration among the Mindset, MSRD and Otsuka Pharmaceuticals teams, Mindset has successfully moved its Family 2 program forward.

Key Points: 
  • Through a world class scientific collaboration among the Mindset, MSRD and Otsuka Pharmaceuticals teams, Mindset has successfully moved its Family 2 program forward.
  • After extensively screening multiple drug candidates in preclinical studies, we were able to identify not one, but two novel drug candidates to potentially advance to clinical human trials.
  • We are delighted to have reached this major milestone in our programs development, said James Lanthier, CEO of Mindset Pharma.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.